Browse > Article
http://dx.doi.org/10.14348/molcells.2015.0294

Functions of TET Proteins in Hematopoietic Transformation  

Han, Jae-A (School of Life Sciences, Ulsan National Institute of Science and Technology)
An, Jungeun (Center for Genomic Integrity, Institute for Basic Science (IBS))
Ko, Myunggon (School of Life Sciences, Ulsan National Institute of Science and Technology)
Publication Information
Molecules and Cells / v.38, no.11, 2015 , pp. 925-935 More about this Journal
Abstract
DNA methylation is a well-characterized epigenetic modification that plays central roles in mammalian development, genomic imprinting, X-chromosome inactivation and silencing of retrotransposon elements. Aberrant DNA methylation pattern is a characteristic feature of cancers and associated with abnormal expression of oncogenes, tumor suppressor genes or repair genes. Ten-eleven-translocation (TET) proteins are recently characterized dioxygenases that catalyze progressive oxidation of 5-methylcytosine to produce 5-hydroxymethylcytosine and further oxidized derivatives. These oxidized methylcytosines not only potentiate DNA demethylation but also behave as independent epigenetic modifications per se. The expression or activity of TET proteins and DNA hydroxymethylation are highly dysregulated in a wide range of cancers including hematologic and non-hematologic malignancies, and accumulating evidence points TET proteins as a novel tumor suppressor in cancers. Here we review DNA demethylation-dependent and -independent functions of TET proteins. We also describe diverse TET loss-of-function mutations that are recurrently found in myeloid and lymphoid malignancies and their potential roles in hematopoietic transformation. We discuss consequences of the deficiency of individual Tet genes and potential compensation between different Tet members in mice. Possible mechanisms underlying facilitated oncogenic transformation of TET-deficient hematopoietic cells are also described. Lastly, we address non-mutational mechanisms that lead to suppression or inactivation of TET proteins in cancers. Strategies to restore normal 5mC oxidation status in cancers by targeting TET proteins may provide new avenues to expedite the development of promising anti-cancer agents.
Keywords
5-methylcytosine oxidation; hematopoiesis; hematologic malignancies; TET protein; tumor suppression;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Suzuki, M.M., and Bird, A. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9, 465-476.
2 Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.   DOI
3 Tefferi, A., Levine, R.L., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Finke, C.M., Mullally, A., Li, C.Y., Pardanani, A., et al. (2009). Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23, 900-904.   DOI
4 Thol, F., Weissinger, E.M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010). IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95, 1668-1674.   DOI
5 Traina, F., Visconte, V., Jankowska, A.M., Makishima, H., O'Keefe, C.L., Elson, P., Han, Y.C., Hsieh, F.H., Sekeres, M.A., Mali, R.S., et al. (2012). Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLos One 7, e43090.   DOI
6 Valinluck, V., and Sowers, L.C. (2007). Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67, 946-950.   DOI
7 Viguie, F., Aboura, A., Bouscary, D., Ramond, S., Delmer, A., Tachdjian, G., Marie, J.P., and Casadevall, N. (2005). Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19, 1411-1415.   DOI
8 Wang, Y., and Zhang, Y. (2014). Regulation of TET protein stability by Calpains. Cell Rep. 6, 278-284.   DOI
9 Wang, L.F., Zhou, Y., Xu, L., Xiao, R., Lu, X.Y., Chen, L., Chong, J., Li, H.R., He, C., Fu, X.D., et al. (2015a). Molecular basis for 5- carboxycytosine recognition by RNA polymerase II elongation complex. Nature 523, 621-625.   DOI
10 Wang, Y.P., Xiao, M.T., Chen, X.F., Chen, L.L., Xu, Y.P., Lv, L., Wang, P., Yang, H., Ma, S.H., Lin, H.P., et al. (2015b). WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662-673.   DOI
11 Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234.   DOI
12 Wu, H., and Zhang, Y. (2014). Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156, 45-68.   DOI
13 Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., et al. (2011a). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30.   DOI
14 Xu, Y.F., Wu, F.Z., Tan, L., Kong, L.C., Xiong, L.J., Deng, J., Barbera, A.J., Zheng, L.J., Zhang, H.K., Huang, S., et al. (2011b). Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 42, 451-464.   DOI
15 Xu, Y.F., Xu, C., Kato, A., Tempel, W., Abreu, J.G., Bian, C.B., Hu, Y.G., Hu, D., Zhao, B., Cerovina, T., et al. (2012). Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell 151, 1200-1213.   DOI
16 Zhang, L., Lu, X., Lu, J., Liang, H., Dai, Q., Xu, G.L., Luo, C., Jiang, H., and He, C. (2012). Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat. Chem. Biol. 8, 328-330.   DOI
17 Yan, H., Parsons, D.W., Jin, G.L., McLendon, R., Rasheed, B.A., Yuan, W.S., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 Mutations in Gliomas. N Engl. J. Med. 360, 765-773.   DOI
18 Yin, R., Mao, S.Q., Zhao, B., Chong, Z., Yang, Y., Zhao, C., Zhang, D., Huang, H., Gao, J., Li, Z., et al. (2013). Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135, 10396-10403.   DOI
19 Zhang, H.K., Zhang, X., Clark, E., Mulcahey, M., Huang, S., and Shi, Y.G. (2010). TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res. 20, 1390-1393.   DOI
20 Zhang, Q., Liu, X.G., Gao, W.Q., Li, P.S., Hou, J.L., Li, J.W., and Wong, J.M. (2014). Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked $\beta$-N-acetylglucosamine transferase (OGT). J. Biol. Chem. 289, 5986-5996.   DOI
21 Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015). Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389-393.   DOI
22 Arita, K., Ariyoshi, M., Tochio, H., Nakamura, Y., and Shirakawa, M. (2008). Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 455, 818-821.   DOI
23 Abbas, S., Lugthart, S., Kavelaars, F.G., Schelen, A., Koenders, J.E., Zeilemaker, A., van Putten, W.J., Rijneveld, A.W., Lowenberg, B., and Valk, P.J. (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116, 2122-2126.   DOI
24 Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y.R., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., Lafave, L.M., et al. (2013). Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641-2659.   DOI
25 Arioka, Y., Watanabe, A., Saito, K., and Yamada, Y. (2012). Activation-induced cytidine deaminase alters the subcellular localization of Tet family proteins. PLos One 7, e45031.   DOI
26 Avvakumov, G.V., Walker, J.R., Xue, S., Li, Y.J., Duan, S.L., Bronner, C., Arrowsmith, C.H., and Dhe-Paganon, S. (2008). Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 455, 822-825.   DOI
27 Bachman, M., Uribe-Lewis, S., Yang, X.P., Williams, M., Murrell, A., and Balasubramanian, S. (2014). 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat. Chem. 6, 1049-1055.   DOI
28 Bachman, M., Uribe-Lewis, S., Yang, X.P., Burgess, H.E., Iurlaro, M., Reik, W., Murrell, A., and Balasubramanian, S. (2015). 5-Formylcytosine can be a stable DNA modification in mammals. Nat. Chem. Biol. 11, 555-557.   DOI
29 Bostick, M., Kim, J.K., Esteve, P.O., Clark, A., Pradhan, S., and Jacobsen, S.E. (2007). UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317, 1760-1764.   DOI
30 Blaschke, K., Ebata, K.T., Karimi, M.M., Zepeda-Martinez, J.A., Goyal, P., Mahapatra, S., Tam, A., Laird, D.J., Hirst, M., Rao, A., et al. (2013). Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500, 222-226.   DOI
31 Busque, L., Patel, J.P., Figueroa, M.E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. (2012). Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179-1181.   DOI
32 Cairns, R.A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.P., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119, 1901-1903.   DOI
33 Challen, G.A., Sun, D.Q., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H.C., Xi, Y.X., et al. (2012). Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23-31.   DOI
34 Chang, Y.I., Damnernsawad, A., Allen, L.K., Yang, D., Ranheim, E.A., Young, K.H., Zhang, J.F., Kong, G.Y., Wang, J.Y., Liu, Y.G., et al. (2014). Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation. Br. J. Haematol. 166, 461-465.   DOI
35 Chen, C.C., Wang, K.Y., and Shen, C.K. (2012). The mammalian de novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine dehydroxymethylases. J. Biol. Chem. 287, 33116-33121.   DOI
36 Couronne, L., Bastard, C., and Bernard, O.A. (2012). TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl. J. Med. 366, 95-96.   DOI
37 Cheng, J.J., Guo, S.Q., Chen, S.N., Mastriano, S.J., Liu, C.C., D'Alessio, A.C., Hysolli, E., Guo, Y.W., Yao, H., Megyola, C.M., et al. (2013). An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 5, 471-481.   DOI
38 Chim, C.S., Wan, T.S., Fung, T.K., and Wong, K.F. (2010). Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J. Clin. Pathol. 63, 942-946.   DOI
39 Cimmino, L., Dawlaty, M.M., Ndiaye-Lobry, D., Yap, Y.S., Bakogianni, S., Yu, Y., Bhattacharyya, S., Shaknovich, R., Geng, H., Lobry, C., et al. (2015). TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653-662.   DOI
40 Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.   DOI
41 De Vita, S., Schneider, R.K., Garcia, M., Wood, J., Gavillet, M., Ebert, B.L., Gerbaulet, A., Roers, A., Levine, R.L., Mullally, A., et al. (2014). Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One 9, e96209.   DOI
42 Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., et al. (2009). Mutation in TET2 in myeloid cancers. N Engl. J. Med. 360, 2289-2301.   DOI
43 Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S.F., Schenkein, D.P., Su, S.S.M., et al. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344.   DOI
44 Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567.   DOI
45 Fu, X.H., Jin, L., Wang, X.C., Luo, A., Hu, J.K., Zheng, X.W., Tsark, W.M., Riggs, A.D., Ku, H.T., and Huang, W.D. (2013). MicroRNA- 26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc. Natl. Acad. Sci. USA 110, 17892-17897.   DOI
46 Gelsi-Boyer, V., Trouplin, V., Roquain, J., Adelaide, J., Carbuccia, N., Esterni, B., Finetti, P., Murati, A., Arnoulet, C., Zerazhi, H., et al. (2010). ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br. J. Haematol. 151, 365-375.   DOI
47 Guo, J.U., Su, Y.J., Zhong, C., Ming, G.L., and Song, H.J. (2011). Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434.   DOI
48 Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014). Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247.   DOI
49 Hashimoto, H., Horton, J.R., Zhang, X., Bostick, M., Jacobsen, S.E., and Cheng, X.D. (2008). The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 455, 826-829.   DOI
50 Hanssens, K., Brenet, F., Agopian, J., Georgin-Lavialle, S., Damaj, G., Cabaret, L., Chandesris, M.O., de Sepulveda, P., Hermine, O., Dubreuil, P., et al. (2014). SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 99, 830-835.   DOI
51 Hashimoto, H., Liu, Y., Upadhyay, A.K., Chang, Y., Howerton, S.B., Vertino, P.M., Zhang, X., and Cheng, X. (2012). Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 40, 4841-4849.   DOI
52 Hashimoto, H., Zhang, X., and Cheng, X.D. (2013). Selective excision of 5-carboxylcytosine by a thymine DNA glycosylase mutant. J. Mol. Biol. 425, 971-976.   DOI
53 Hashimoto, H., Olanrewaju, Y.O., Zheng, Y., Wilson, G.G., Zhang, X., and Cheng, X.D. (2014). Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence. Genes Dev. 28, 2304-2313.   DOI
54 He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-1307.   DOI
55 Hino, S., Kishida, S., Michiue, T., Fukui, A., Sakamoto, I., Takada, S., Asashima, M., and Kikuchi, A. (2001). Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol. Cell Biol. 21, 330-342.   DOI
56 Huang, Y., Pastor, W.A., Shen, Y.H., Tahiliani, M., Liu, D.R., and Rao, A. (2010). The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLos One 5, e8888.   DOI
57 Hon, G.C., Song, C.X., Du, T.T., Jin, F.L., Selvaraj, S., Lee, A.Y., Yen, C.A., Ye, Z., Mao, S.Q., Wang, B.A., et al. (2014). 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell 56, 286-297.   DOI
58 Hu, L.L., Li, Z., Cheng, J.D., Rao, Q.H., Gong, W., Liu, M.J., Shi, Y.J.G., Zhu, J.Y., Wang, P., and Xu, Y.H. (2013). Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell 155, 1545-1555.   DOI
59 Huang, Y., and Rao, A. (2014). Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet. 30, 464-474.   DOI
60 Huang, H., Jiang, X., Li, Z., Li, Y., Song, C.X., He, C., Sun, M., Chen, P., Gurbuxani, S., Wang, J., et al. (2013). TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 110, 11994-11999.   DOI
61 Huang, Y., Chavez, L., Chang, X., Wang, X., Pastor, W.A., Kang, J., Zepeda-Martinez, J.A., Pape, U.J., Jacobsen, S.E., Peters, B., et al. (2014). Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 111, 1361-1366.   DOI
62 Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., and Zhang, Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303.   DOI
63 Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Ades, L., Fenaux, P., Platzbecker, U., Gagey, O., et al. (2013). Clonal architecture of chronic myelomonocytic leukemias. Blood 121, 2186-2198.   DOI
64 Kats, L.M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K., Karnik, R., Meissner, A., Small, D., et al. (2014). Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14, 329-341.   DOI
65 Iurlaro, M., Ficz, G., Oxley, D., Raiber, E.A., Bachman, M., Booth, M.J., Andrews, S., Balasubramanian, S., and Reik, W. (2013). A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol. 14, R119.   DOI
66 Iyer, L.M., Tahiliani, M., Rao, A., and Aravind, L. (2009). Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8, 1698-1710.   DOI
67 Iyer, L.M., Abhiman, S., and Aravind, L. (2011). Natural history of eukaryotic DNA methylation systems. Prog. Mol. Biol. Transl. Sci. 101, 25-104.   DOI
68 Kellinger, M.W., Song, C.X., Chong, J., Lu, X.Y., He, C., and Wang, D. (2012). 5-formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nat. Struct. Mol. Biol. 19, 831-833.   DOI
69 Kim, Y.H., Pierscianek, D., Mittelbronn, M., Vital, A., Mariani, L., Hasselblatt, M., and Ohgaki, H. (2011). TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol. 64, 850-852.   DOI
70 Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843.   DOI
71 Kojima, T., Shimazui, T., Hinotsu, S., Joraku, A., Oikawa, T., Kawai, K., Horie, R., Suzuki, H., Nagashima, R., Yoshikawa, K., et al. (2009). Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 28, 297-305.   DOI
72 Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B., and Rao, A. (2011). Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. USA 108, 14566-14571.   DOI
73 Ko, M., An, J., Bandukwala, H.S., Chavez, L., Aijo, T., Pastor, W.A., Segal, M.F., Li, H.M., Koh, K.P., Lahdesmaki, H., et al. (2013). Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497, 122-126.   DOI
74 Ko, M., An, J., Pastor, W.A., Koralov, S.B., Rajewsky, K., and Rao, A. (2015). TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6-21.   DOI
75 Konstandin, N., Bultmann, S., Szwagierczak, A., Dufour, A., Ksienzyk, B., Schneider, F., Herold, T., Mulaw, M., Kakadia, P.M., Schneider, S., et al. (2011). Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25, 1649-1652.   DOI
76 Kunimoto, H., Fukuchi, Y., Sakurai, M., Sadahira, K., Ikeda, Y., Okamoto, S., and Nakajima, H. (2012). Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci. Rep. 2, 273.   DOI
77 Kunimoto, H., Fukuchi, Y., Sakurai, M., Takubo, K., Okamoto, S., and Nakajima, H. (2014). Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity. Blood 123, 2897- 2899.   DOI
78 Li, Z., Cai, X., Cai, C.L., Wang, J., Zhang, W., Petersen, B.E., Yang, F.C., and Xu, M. (2011). Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509-4518.   DOI
79 Langemeijer, S.M.C., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G., Raymakers, R.A.P., et al. (2009). Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41, 838-842.   DOI
80 Lemonnier, F., Couronne, L., Parrens, M., Jais, J.P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R.A., et al. (2012). Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with T-FH-like features and adverse clinical parameters. Blood 120, 1466-1469.   DOI
81 Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T., and Downing, J.R. (2003). TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637-641.   DOI
82 Lu, F.L., Liu, Y.T., Jiang, L., Yamaguchi, S., and Zhang, Y. (2014). Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev. 28, 2103-2119.   DOI
83 Maiti, A., and Drohat, A.C. (2011). Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol. Chem. 286, 35334-35338.   DOI
84 Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012). SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120, 3080-3088.   DOI
85 Nakagawa, T., Lv, L., Nakagawa, M., Yu, Y.B., Yu, C., D'Alessio, A.C., Nakayama, K., Fan, H.Y., Chen, X., and Xiong, Y. (2015). CRL4(VprBP) E3 Ligase Promotes Monoubiquitylation and Chromatin Binding of TET Dioxygenases. Mol. Cell 57, 247-260.   DOI
86 Minor, E.A., Court, B.L., Young, J.I., and Wang, G.F. (2013). Ascorbate Induces Ten-Eleven Translocation (Tet) Methylcytosine Dioxygenase-mediated Generation of 5-Hydroxymethylcytosine. J. Biol. Chem. 288, 13669-13674.   DOI
87 Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24.   DOI
88 Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., et al. (2013). Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 210, 2627-2639.   DOI
89 Odejide, O., Weigert, O., Lane, A.A., Toscano, D., Lunning, M.A., Kopp, N., Kim, S., van Bodegom, D., Bolla, S., Schatz, J.H., et al. (2014). A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293-1296.   DOI
90 Ono, R., Taki, T., Taketani, T., Taniwaki, M., Kobayashi, H., and Hayashi, Y. (2002). LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62, 4075-4080.
91 Ooi, S.K.T., O'Donnell, A.H., and Bestor, T.H. (2009). Mammalian cytosine methylation at a glance. J. Cell Sci. 122, 2787-2791.   DOI
92 Parsons, D.W., Jones, S., Zhang, X.S., Lin, J.C.H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.   DOI
93 Paez, D., Gerger, A., Zhang, W., Yang, D., Labonte, M.J., Benhanim, L., Kahn, M., Lenz, F., Lenz, C., Ning, Y., et al. (2014). Association of common gene variants in the WNT/beta-catenin pathway with colon cancer recurrence. Pharmacogenomics J. 14, 142-150.   DOI
94 Palomero, T., Couronne, L., Khiabanian, H., Kim, M.Y., Ambesi- Impiombato, A., Perez-Garcia, A., Carpenter, Z., Abate, F., Allegretta, M., Haydu, J.E., et al. (2014). Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166-170.   DOI
95 Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., et al. (2013). Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627.   DOI
96 Pastor, W.A., Aravind, L., and Rao, A. (2013). TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14, 341-356.   DOI
97 Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z.X., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl. J. Med. 366, 1079-1089.   DOI
98 Pronier, E., Almire, C., Mokrani, H., Vasanthakumar, A., Simon, A., Mor, B.D.R.M., Masse, A., Le Couedic, J.P., Pendino, F., Carbonne, B., et al. (2011). Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118, 2551-2555.   DOI
99 Raiber, E.A., Murat, P., Chirgadze, D.Y., Beraldi, D., Luisi, B.F., and Balasubramanian, S. (2015). 5-Formylcytosine alters the structure of the DNA double helix. Nat. Struct. Mol. Biol. 22, 44-49.   DOI
100 Quivoron, C., Couronne, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., et al. (2011). TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38.   DOI
101 Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y.S., Ahn, J.H., Abdel-Wahab, O., Shih, A., et al. (2014). DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 9, 1841-1855.   DOI
102 Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y., Muto, H., Tsuyama, N., Sato-Otsubo, A., Okuno, Y., et al. (2014). Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 46, 171-175.   DOI
103 Sasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Brustle, A., Harris, I.S., Holmes, R., Wakeham, A., Haight, J., et al. (2012). IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659.   DOI
104 Schiesser, S., Hackner, B., Pfaffeneder, T., Muller, M., Hagemeier, C., Truss, M., and Carell, T. (2012). Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew. Chem. Int. Ed. Engl. 51, 6516-6520.   DOI
105 Sharif, J., Muto, M., Takebayashi, S.I., Suetake, I., Iwamatsu, A., Endo, T.A., Shinga, J., Mizutani-Koseki, Y., Toyoda, T., Okamura, K., et al. (2007). The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450, 908-912.   DOI
106 Song, S.J., Ito, K., Ala, U., Kats, L., Webster, K., Sun, S.M., Jongen-Lavrencic, M., Manova-Todorova, K., Teruya-Feldstein, J., Avigan, D.E., et al. (2013a). The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell selfrenewal and transformation. Cell Stem Cell 13, 87-101.   DOI
107 Shen, L., Song, C.X., He, C., and Zhang, Y. (2014). Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu. Rev. Biochem. 83, 585-614.   DOI
108 Shide, K., Kameda, T., Shimoda, H., Yamaji, T., Abe, H., Kamiunten, A., Sekine, M., Hidaka, T., Katayose, K., Kubuki, Y., et al. (2012). TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 26, 2216-2223.   DOI
109 Shih, A.H., Jiang, Y.W., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y.M., et al. (2015). Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502-515.   DOI
110 Song, S.J., Poliseno, L., Song, M.S., Ala, U., Webster, K., Ng, C., Beringer, G., Brikbak, N.J., Yuan, X., Cantley, L.C., et al. (2013b). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311-324.   DOI
111 Spruijt, C.G., Gnerlich, F., Smits, A.H., Pfaffeneder, T., Jansen, P.W., Bauer, C., Munzel, M., Wagner, M., Muller, M., Khan, F., et al. (2013). Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 152, 1146-1159.   DOI
112 Sun, M., Song, C.X., Huang, H., Frankenberger, C.A., Sankarasharma, D., Gomes, S., Chen, P., Chen, J.J., Chada, K.K., He, C., et al. (2013). HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. USA 110, 9920-9925.   DOI